NK cell-based immunotherapies against tumors
Abstract Natural killer (NK) cells provide the first line of defence against pathogens and tumors. Their activation status is regulated by pro-inflammatory cytokines and by ligands that either target inhibitory or activating cell surface receptors belonging to the immunoglobulin-like, C-type lectin or natural cytotoxicity receptor families. Apart from non-classical HLA-E, membrane-bound heat shock protein 70 (Hsp70) has been identified as a tumor-specific recognition structure for NK cells expressing high amounts of the C-type lectin receptor CD94, acting as one component of an activating heterodimeric receptor complex. Full-length Hsp70 protein (Hsp70) or the 14-mer Hsp70 peptide T-K-D-N-N-L-L-G-R-F-E-L-S-G (TKD) in combination with pro-inflammatory cytokines enhances the cytolytic activity of NK cells towards Hsp70 membrane-positive tumors. Based on these findings cytokine/TKD-activated NK cells were adoptively transferred in tumor patients. These findings were compared to results of clinical trials using cytokine-activated NK cells..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2006 |
|---|---|
| Erschienen: |
2006 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1 |
|---|---|
| Enthalten in: |
Open medicine - 1(2006), 3 vom: 23. Aug., Seite 179-204 |
| Beteiligte Personen: |
Radons, Jürgen [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
© 2006 Versita Warsaw |
|---|
| doi: |
10.2478/s11536-006-0023-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2138357503 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2138357503 | ||
| 003 | DE-627 | ||
| 005 | 20230810090353.0 | ||
| 007 | tu | ||
| 008 | 230810s2006 xx ||||| 00| ||und c | ||
| 024 | 7 | |a 10.2478/s11536-006-0023-x |2 doi | |
| 035 | |a (DE-627)OLC2138357503 | ||
| 035 | |a (DE-B1597)s11536-006-0023-x-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Radons, Jürgen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NK cell-based immunotherapies against tumors |
| 264 | 1 | |c 2006 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © 2006 Versita Warsaw | ||
| 520 | |a Abstract Natural killer (NK) cells provide the first line of defence against pathogens and tumors. Their activation status is regulated by pro-inflammatory cytokines and by ligands that either target inhibitory or activating cell surface receptors belonging to the immunoglobulin-like, C-type lectin or natural cytotoxicity receptor families. Apart from non-classical HLA-E, membrane-bound heat shock protein 70 (Hsp70) has been identified as a tumor-specific recognition structure for NK cells expressing high amounts of the C-type lectin receptor CD94, acting as one component of an activating heterodimeric receptor complex. Full-length Hsp70 protein (Hsp70) or the 14-mer Hsp70 peptide T-K-D-N-N-L-L-G-R-F-E-L-S-G (TKD) in combination with pro-inflammatory cytokines enhances the cytolytic activity of NK cells towards Hsp70 membrane-positive tumors. Based on these findings cytokine/TKD-activated NK cells were adoptively transferred in tumor patients. These findings were compared to results of clinical trials using cytokine-activated NK cells. | ||
| 650 | 4 | |a Heat shock proteins | |
| 650 | 4 | |a NK cells | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a immunostimulation | |
| 650 | 4 | |a cell therapy | |
| 700 | 1 | |a Stangl, Stefan |4 aut | |
| 700 | 1 | |a Multhoff, Gabriele |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open medicine |d Versita, 2015 |g 1(2006), 3 vom: 23. Aug., Seite 179-204 |h Online-Ressource |w (DE-627)832299049 |w (DE-600)2829380-0 |w (DE-576)442600356 |x 2391-5463 |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:2006 |g number:3 |g day:23 |g month:08 |g pages:179-204 |
| 856 | 4 | 1 | |u https://doi.org/10.2478/s11536-006-0023-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 2006 |e 3 |b 23 |c 08 |h 179-204 | ||